Sam Altman suggested it would be released more widely than a rival offering from Anthropic. Some are suggesting it’s because ...

New ChatGPT Images 2.0 claims a step up in thinking capabilities, detailed instruction following, and improved rendering of ...

Add Decrypt as your preferred source to see more of our stories on Google. OpenAI unveiled GPT-Rosalind to accelerate drug discovery workflows. Benchmarks show strong gains, but real-world impact ...

Bill Peebles, who led OpenAI's defunct short-form video app Sora, and Kevin Weil, the vice president of OpenAI for Science, announced their departures on Friday. Srinivas Narayanan, who worked in B2B ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...

The former Instagram VP is departing the ChatGPT-maker, which is folding the AI science application he led into Codex. Kevin Weil, OpenAI’s former chief product officer who was recently tapped to ...

When Sam Altman was briefly fired, then rehired as OpenAI CEO in 2023, the company’s board of directors had fretted over what little they knew about his personal investments and whether they posed ...

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to support research in biology, drug discovery and translational medicine.

The Silicon Valley chip maker filed a prospectus just as SpaceX, Anthropic and OpenAI prepared for their own listings, in what is shaping up to be a wave of enormous initial public offerings. By Cade ...

I have zero coding skills, but I was able to quickly assemble camera feeds from around the world into a single view. Here's how I did it—and what it means for all of us. I'm the Executive Editor, ...

On April 17, 2026, OpenAI introduced GPT-Rosalind, an artificial intelligence model specifically engineered for biological research and pharmaceutical development The technology targets reduction of ...

OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way ...